Spectral Medical Completes Tigris Trial Enrollment

157 patients enrolled Topline results expected to be released in August 2025 Company to host Corporate Update Call on May 15, 2025 TORONTO, Canada – April 16, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company...
Read More

Spectral Medical Provides February Tigris Trial Update

152 patients enrolled TORONTO, Canada – March 3, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris...
Read More

Spectral Medical Provides January Tigris Trial Update

Strong enrollment activity to start 2025 146 patients enrolled TORONTO, Canada – February 3, 2025 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today...
Read More

Spectral Medical Provides December Tigris Trial Update

140 patients enrolled. TORONTO, Canada – January 6, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris...
Read More
Click to Hide Advanced Floating Content
EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.